icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
AY4Sq2rdHdFuYyps
Listen
